Patent details

Basic Information

Publication number:

EP3454898

PCT Application Number:

US2017031771

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP177250149

PCT Publication Number:

WO2017196854

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

DRUG COMBINATIONS FOR REDUCING CELL VIABILITY AND/OR CELL PROLIFERATION

French Title of Invention:

ASSOCIATIONS MÉDICAMENTEUSES PERMETTANT DE RÉDUIRE LA VIABILITÉ ET/OU LA PROLIFÉRATION CELLULAIRE

German Title of Invention:

ARZNEIMITTELKOMBINATIONEN ZUR VERRINGERUNG DER ZELLLEBENSFÄHIGKEIT UND/ODER ZELLPROLIFERATION

SPC Number:

Dates

Filing date:

09/05/2017

Grant date:

10/11/2021

EP Publication Date:

20/03/2019

PCT Publication Date:

16/11/2017

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

10/11/2021

EP B1 Publication Date:

10/11/2021

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

09/05/2022

Expiration date:

09/05/2037

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

03/11/2021

 

 

Name:

Eisai R&D Management Co., Ltd.

Address:

6-10, Koishikawa 4-chome Bunkyo-ku, Tokyo 112-8088, Japan (JP)

Inventor

1

Name:

SMITH, Peter

Address:

United States (US)

2

Name:

SELVARAJ, Anand

Address:

United States (US)

Priority

Priority Number:

201662334102 P

Priority Date:

10/05/2016

Priority Country:

United States (US)

Classification

IPC classification:

A61K 39/395; A61K 31/4706; A61K 31/506; A61K 31/517; A61P 35/00;

Publication

European Patent Bulletin

Issue number:

202145

Publication date:

10/11/2021

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages